More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...
4don MSN
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...
7don MSN
Exclusive: India proposes forcing smartphone makers to give source code in security overhaul
The plan is part of Prime Minister Narendra Modi's efforts to boost security of user data as online fraud and data breaches ...
MedPage Today on MSN
FDA Has Taken Cautious Approach With Mifepristone, Review Suggests
Three key themes emerged across the mifepristone documents: consistent safety findings, lack of ideological bias in staff ...
PDF Agile is designed to help business owners handle those documents more efficiently. It brings editing, converting, signing, and securing PDFs into a single desktop tool, reducing the need to switch ...
Amazon Alexa browser version launches as Alexa.com for Early Access users with Alexa+ subscriptions and compatible Echo ...
The National Council on Teacher Quality has given failing grades to three public universities in Maine for how their teacher preparation programs teach reading ...
The plan is part of Prime Minister Narendra Modi’s efforts to boost security of user data as online fraud and data breaches ...
For organizations that conduct background checks, 2025 was not just about tracking new laws. It was about rethinking how ...
The White House says the Smithsonian Institution must submit materials about current and upcoming exhibitions and events for ...
FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results